Basic and clinical studies on cefdinir

Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Toshiyuki Ishimaru, Koji Takaki, Nobuyuki Shimono, Yoshiyuki Niho, Masahide Takii, Hidenobu Shigeoka, Kenji Kono, Atsushi Takita, Michio Fukuma, Takatoshi Yamane, Kazuhiro Hayashida, Noriaki Suzuki, Kiyoshi Ninomiya

Research output: Contribution to journalArticle

Abstract

We performed basic and clinical studies on cefdinir (CFDN), a new cephalosporin antibiotic, with the following results. 1. Antimicrobial activity The MIC80 of CFDN against various clinical isolates was as follows: 0.78 μg/ml against Staphylococcus aureus, 12.5 μg/ml against Enterococcus faecalis, 0.39 μg/ml against Escherichia coli, 0.78 μg/ml against Klebsiella pneumoniae, >100 μg/ml against Enterobacter spp., 50 μg/ml against Serratia marcescens, 0.78 μg/ml against Proteus mirabilis, 12.5 μg/ml against Proteus vulgaris, 100 μg/ml against Citrobacter spp. and>100 μg/ml against Psedomonas spp. The activity of CFDN against Gram-postive cocci was 3-4 times stronger than that of cefaclor (CCL), and 5-6 times stronger than that of cefixime (CFIX). The activity against E. coli, K. pneumoniae and Citrobacter spp. was about the same as that of CFIX, and against other Gram-negative bacilli it was less than that of CFIX. On the other hand, the activity of CFDN was much stronger than that of CCL. 2. Clinical efficacy One patient with pneumonia, 18 with bronchitis, 5 with tonsillitis or pharyngitis, 4 with pyelonephritis, 3 with cystitis, 1 with prostatitis, and 1 with thrombophlehitis were treated with CFDN in a daily dose of 200-600 mg for 2-32 days. Clinical response was excellent in 5 patients, good in 18, fair in 8, poor in 1 and unknown in 1. The clinical efficacy rate was 71.9%. CFDN was more effective in acute upper respiratory tract infections, pneumonia, and urinary tract infections. As for adverse reactions, diarrhea or loose stool were noted in 2 patients. As abnormal laboratory data, eosinophilia was seen in 2 patients, and elevated GOT and GPT or GPT alone were observed in 2.

Original languageEnglish
Pages (from-to)540-553
Number of pages14
JournalChemotherapy
Volume37
DOIs
Publication statusPublished - Jan 1 1989

Fingerprint

cefdinir
Cefixime
Citrobacter
Cefaclor
Klebsiella pneumoniae
Pneumonia
Proteus vulgaris
Escherichia coli
Proteus mirabilis
Tonsillitis
Enterobacter
Prostatitis
Serratia marcescens
Cystitis
Pharyngitis
Bronchitis
Enterococcus faecalis
Pyelonephritis
Eosinophilia
Cephalosporins

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Sawae, Y., Okada, K., Kumagai, Y., Ishimaru, T., Takaki, K., Shimono, N., ... Ninomiya, K. (1989). Basic and clinical studies on cefdinir. Chemotherapy, 37, 540-553. https://doi.org/10.11250/chemotherapy1953.37.Supplement2_540

Basic and clinical studies on cefdinir. / Sawae, Yoshiro; Okada, Kaoru; Kumagai, Yukio; Ishimaru, Toshiyuki; Takaki, Koji; Shimono, Nobuyuki; Niho, Yoshiyuki; Takii, Masahide; Shigeoka, Hidenobu; Kono, Kenji; Takita, Atsushi; Fukuma, Michio; Yamane, Takatoshi; Hayashida, Kazuhiro; Suzuki, Noriaki; Ninomiya, Kiyoshi.

In: Chemotherapy, Vol. 37, 01.01.1989, p. 540-553.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Kumagai, Y, Ishimaru, T, Takaki, K, Shimono, N, Niho, Y, Takii, M, Shigeoka, H, Kono, K, Takita, A, Fukuma, M, Yamane, T, Hayashida, K, Suzuki, N & Ninomiya, K 1989, 'Basic and clinical studies on cefdinir', Chemotherapy, vol. 37, pp. 540-553. https://doi.org/10.11250/chemotherapy1953.37.Supplement2_540
Sawae Y, Okada K, Kumagai Y, Ishimaru T, Takaki K, Shimono N et al. Basic and clinical studies on cefdinir. Chemotherapy. 1989 Jan 1;37:540-553. https://doi.org/10.11250/chemotherapy1953.37.Supplement2_540
Sawae, Yoshiro ; Okada, Kaoru ; Kumagai, Yukio ; Ishimaru, Toshiyuki ; Takaki, Koji ; Shimono, Nobuyuki ; Niho, Yoshiyuki ; Takii, Masahide ; Shigeoka, Hidenobu ; Kono, Kenji ; Takita, Atsushi ; Fukuma, Michio ; Yamane, Takatoshi ; Hayashida, Kazuhiro ; Suzuki, Noriaki ; Ninomiya, Kiyoshi. / Basic and clinical studies on cefdinir. In: Chemotherapy. 1989 ; Vol. 37. pp. 540-553.
@article{f54dea2017254cefac73692ee314caca,
title = "Basic and clinical studies on cefdinir",
abstract = "We performed basic and clinical studies on cefdinir (CFDN), a new cephalosporin antibiotic, with the following results. 1. Antimicrobial activity The MIC80 of CFDN against various clinical isolates was as follows: 0.78 μg/ml against Staphylococcus aureus, 12.5 μg/ml against Enterococcus faecalis, 0.39 μg/ml against Escherichia coli, 0.78 μg/ml against Klebsiella pneumoniae, >100 μg/ml against Enterobacter spp., 50 μg/ml against Serratia marcescens, 0.78 μg/ml against Proteus mirabilis, 12.5 μg/ml against Proteus vulgaris, 100 μg/ml against Citrobacter spp. and>100 μg/ml against Psedomonas spp. The activity of CFDN against Gram-postive cocci was 3-4 times stronger than that of cefaclor (CCL), and 5-6 times stronger than that of cefixime (CFIX). The activity against E. coli, K. pneumoniae and Citrobacter spp. was about the same as that of CFIX, and against other Gram-negative bacilli it was less than that of CFIX. On the other hand, the activity of CFDN was much stronger than that of CCL. 2. Clinical efficacy One patient with pneumonia, 18 with bronchitis, 5 with tonsillitis or pharyngitis, 4 with pyelonephritis, 3 with cystitis, 1 with prostatitis, and 1 with thrombophlehitis were treated with CFDN in a daily dose of 200-600 mg for 2-32 days. Clinical response was excellent in 5 patients, good in 18, fair in 8, poor in 1 and unknown in 1. The clinical efficacy rate was 71.9{\%}. CFDN was more effective in acute upper respiratory tract infections, pneumonia, and urinary tract infections. As for adverse reactions, diarrhea or loose stool were noted in 2 patients. As abnormal laboratory data, eosinophilia was seen in 2 patients, and elevated GOT and GPT or GPT alone were observed in 2.",
author = "Yoshiro Sawae and Kaoru Okada and Yukio Kumagai and Toshiyuki Ishimaru and Koji Takaki and Nobuyuki Shimono and Yoshiyuki Niho and Masahide Takii and Hidenobu Shigeoka and Kenji Kono and Atsushi Takita and Michio Fukuma and Takatoshi Yamane and Kazuhiro Hayashida and Noriaki Suzuki and Kiyoshi Ninomiya",
year = "1989",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.37.Supplement2_540",
language = "English",
volume = "37",
pages = "540--553",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on cefdinir

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Kumagai, Yukio

AU - Ishimaru, Toshiyuki

AU - Takaki, Koji

AU - Shimono, Nobuyuki

AU - Niho, Yoshiyuki

AU - Takii, Masahide

AU - Shigeoka, Hidenobu

AU - Kono, Kenji

AU - Takita, Atsushi

AU - Fukuma, Michio

AU - Yamane, Takatoshi

AU - Hayashida, Kazuhiro

AU - Suzuki, Noriaki

AU - Ninomiya, Kiyoshi

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We performed basic and clinical studies on cefdinir (CFDN), a new cephalosporin antibiotic, with the following results. 1. Antimicrobial activity The MIC80 of CFDN against various clinical isolates was as follows: 0.78 μg/ml against Staphylococcus aureus, 12.5 μg/ml against Enterococcus faecalis, 0.39 μg/ml against Escherichia coli, 0.78 μg/ml against Klebsiella pneumoniae, >100 μg/ml against Enterobacter spp., 50 μg/ml against Serratia marcescens, 0.78 μg/ml against Proteus mirabilis, 12.5 μg/ml against Proteus vulgaris, 100 μg/ml against Citrobacter spp. and>100 μg/ml against Psedomonas spp. The activity of CFDN against Gram-postive cocci was 3-4 times stronger than that of cefaclor (CCL), and 5-6 times stronger than that of cefixime (CFIX). The activity against E. coli, K. pneumoniae and Citrobacter spp. was about the same as that of CFIX, and against other Gram-negative bacilli it was less than that of CFIX. On the other hand, the activity of CFDN was much stronger than that of CCL. 2. Clinical efficacy One patient with pneumonia, 18 with bronchitis, 5 with tonsillitis or pharyngitis, 4 with pyelonephritis, 3 with cystitis, 1 with prostatitis, and 1 with thrombophlehitis were treated with CFDN in a daily dose of 200-600 mg for 2-32 days. Clinical response was excellent in 5 patients, good in 18, fair in 8, poor in 1 and unknown in 1. The clinical efficacy rate was 71.9%. CFDN was more effective in acute upper respiratory tract infections, pneumonia, and urinary tract infections. As for adverse reactions, diarrhea or loose stool were noted in 2 patients. As abnormal laboratory data, eosinophilia was seen in 2 patients, and elevated GOT and GPT or GPT alone were observed in 2.

AB - We performed basic and clinical studies on cefdinir (CFDN), a new cephalosporin antibiotic, with the following results. 1. Antimicrobial activity The MIC80 of CFDN against various clinical isolates was as follows: 0.78 μg/ml against Staphylococcus aureus, 12.5 μg/ml against Enterococcus faecalis, 0.39 μg/ml against Escherichia coli, 0.78 μg/ml against Klebsiella pneumoniae, >100 μg/ml against Enterobacter spp., 50 μg/ml against Serratia marcescens, 0.78 μg/ml against Proteus mirabilis, 12.5 μg/ml against Proteus vulgaris, 100 μg/ml against Citrobacter spp. and>100 μg/ml against Psedomonas spp. The activity of CFDN against Gram-postive cocci was 3-4 times stronger than that of cefaclor (CCL), and 5-6 times stronger than that of cefixime (CFIX). The activity against E. coli, K. pneumoniae and Citrobacter spp. was about the same as that of CFIX, and against other Gram-negative bacilli it was less than that of CFIX. On the other hand, the activity of CFDN was much stronger than that of CCL. 2. Clinical efficacy One patient with pneumonia, 18 with bronchitis, 5 with tonsillitis or pharyngitis, 4 with pyelonephritis, 3 with cystitis, 1 with prostatitis, and 1 with thrombophlehitis were treated with CFDN in a daily dose of 200-600 mg for 2-32 days. Clinical response was excellent in 5 patients, good in 18, fair in 8, poor in 1 and unknown in 1. The clinical efficacy rate was 71.9%. CFDN was more effective in acute upper respiratory tract infections, pneumonia, and urinary tract infections. As for adverse reactions, diarrhea or loose stool were noted in 2 patients. As abnormal laboratory data, eosinophilia was seen in 2 patients, and elevated GOT and GPT or GPT alone were observed in 2.

UR - http://www.scopus.com/inward/record.url?scp=0024851216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024851216&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.37.Supplement2_540

DO - 10.11250/chemotherapy1953.37.Supplement2_540

M3 - Article

VL - 37

SP - 540

EP - 553

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -